Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene...

Source: BMC Cancer - August 6, 2018 Category: Cancer & Oncology Authors: Kyriakos P. Papadopoulos, Eytan Ben-Ami, Amita Patnaik, Denise Trone, Jianke Li and George D. Demetri Tags: Research article Source Type: research